Julia Heinzelbecker

Prof. Dr. Julia Heinzelbecker


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Urologia Internationalis
Verified
Journal Article
Open access
PDF file
SKSabine Kliesch
Sabine Kliesch
SSStefanie Schmidt
Stefanie Schmidt
DWDoris Wilborn
Doris Wilborn
CAClemens Aigner
Clemens Aigner
WAWalter Albrecht
Walter Albrecht
PAPeter Albers
Peter Albers
Introduction: This is the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up on germ cell tumours (GCTs) of the testis in adult patients. We present the guideline content in two publications. Part I covers the topic’s background, methods, epidemiology, classification systems, diagnostics, prognosis, and treatment recommendations for the localized stages. Methods: An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search was in March 2018) were provided. Thirty-one experts entitled to vote, rated the final clinical recommendations and statements. Results: We provide 161 clinical recommendations and statements. We present information on the quality of cancer care and epidemiology and give recommendations for staging and classification as well as for diagnostic procedures. The diagnostic recommendations encompass measures for assessing the primary tumour as well as procedures for the detection of metastases. One chapter addresses prognostic factors. In part I, we separately present the treatment recommendations for germ cell neoplasia in situ, and the organ-confined stages (clinical stage I) of both seminoma and nonseminoma. Conclusion: Although GCT is a rare tumour entity with excellent survival rates for the localized stages, its management requires an interdisciplinary approach, including several clinical experts. Quality of care is highly related to institutional expertise and can be reassured by established online-based second-opinion boards. There are very few studies on diagnostics with good level of evidence. Treatment of metastatic GCTs must be tailored to the risk according to the International Germ Cell Cancer Collaboration Group classification after careful diagnostic evaluation. An interdisciplinary approach as well as the referral of selected patients to centres with proven experience can help achieve favourable clinical outcomes.

24 September 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SBSophie Baumgart
Sophie Baumgart
PMPascal Meschkat
Pascal Meschkat
PEPhilipp Edelmann
Philipp Edelmann
JHJoana Heinzelmann
Joana Heinzelmann
APAlexey Pryalukhin
Alexey Pryalukhin
Kerstin JunkerKerstin Junker
Kerstin Junker

15 November 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GBGazanfer Belge
Gazanfer Belge
CDCansu Dumlupinar
Cansu Dumlupinar
TNTim Nestler
Tim Nestler
MKMarkus Klemke
Markus Klemke
PTPeter Törzsök
Peter Törzsök
KDKlaus-Peter Dieckmann
Klaus-Peter Dieckmann
Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.

22 January 2021 in Urologia Internationalis
Verified
Journal Article
Open access
PDF file
SKSabine Kliesch
Sabine Kliesch
SSStefanie Schmidt
Stefanie Schmidt
DWDoris Wilborn
Doris Wilborn
CAClemens Aigner
Clemens Aigner
WAWalter Albrecht
Walter Albrecht
PAPeter Albers
Peter Albers
Objectives: We developed the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up of germ cell tumours (GCT) of the testes in adult patients. We present the guideline content in 2 separate publications. The present second part summarizes therecommendations for the treatment of advanced disease stages and for the management of follow-up and late effects. Materials and Methods: An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search in March 2018), were provided. Thirty-one experts, who were entitled to vote, rated the final clinical recommendations and statements. Results: Here we present the treatment recommendations separately for patients with metastatic seminoma and non-seminomatous GCT (stages IIA/B and IIC/III), for restaging and treatment of residual masses, and for relapsed and refractory disease stages. The recommendations also cover extragonadal and sex cord/stromal tumours, the management of follow-up and toxicity, quality-of-life aspects, palliative care, and supportive therapy. Conclusion: Physicians and other medical service providers who are involved in the diagnostics, treatment, and follow-up of GCT (all stages, outpatient and inpatient care as well as rehabilitation) are the users of the present guideline. The guideline also comprises quality indicators for measuring the implementation of the guideline recommendations in routine clinical care; these data will be presented in a future publication.

1 September 2021 in Surgical Oncology
Verified
Journal Article
Closed access
PZPhilip Zeuschner
Philip Zeuschner
SVSarah Grosse Vollmer
Sarah Grosse Vollmer
JLJohannes Linxweiler
Johannes Linxweiler
GWGudrun Wagenpfeil
Gudrun Wagenpfeil
SWStefan Wagenpfeil
Stefan Wagenpfeil
JHJulia Heinzelbecker
Julia Heinzelbecker

23 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HAHiresh Ayoubian
Hiresh Ayoubian
JHJoana Heinzelmann
Joana Heinzelmann
SHSebastian Hölters
Sebastian Hölters
OKOybek Khalmurzaev
Oybek Khalmurzaev
APAlexey Pryalukhin
Alexey Pryalukhin
Kerstin JunkerKerstin Junker
Kerstin Junker
Although microRNAs are described as promising biomarkers in many tumor types, little is known about their role in PSCC. Thus, we attempted to identify miRNAs involved in tumor development and metastasis in distinct histological subtypes considering the impact of HPV infection. In a first step, microarray analyses were performed on RNA from formalin-fixed, paraffin-embedded tumor (22), and normal (8) tissue samples. Microarray data were validated for selected miRNAs by qRT-PCR on an enlarged cohort, including 27 tumor and 18 normal tissues. We found 876 significantly differentially expressed miRNAs (p ≤ 0.01) between HPV-positive and HPV-negative tumor samples by microarray analysis. Although no significant differences were detected between normal and tumor tissue in the whole cohort, specific expression patterns occurred in distinct histological subtypes, such as HPV-negative usual PSCC (95 differentially expressed miRNAs, p ≤ 0.05) and HPV-positive basaloid/warty subtypes (247 differentially expressed miRNAs, p ≤ 0.05). Selected miRNAs were confirmed by qRT-PCR. Furthermore, microarray data revealed 118 miRNAs (p ≤ 0.01) that were significantly differentially expressed in metastatic versus non-metastatic usual PSCC. The lower expression levels for miR-137 and miR-328-3p in metastatic usual PSCC were validated by qRT-PCR. The results of this study confirmed that specific miRNAs could serve as potential diagnostic and prognostic markers in single PSCC subtypes and are associated with HPV-dependent pathways.